Compare FELE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FELE | NAMS |
|---|---|---|
| Founded | 1944 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.6B |
| IPO Year | 1995 | N/A |
| Metric | FELE | NAMS |
|---|---|---|
| Price | $98.39 | $35.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $103.50 | $46.75 |
| AVG Volume (30 Days) | 217.8K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $2,131,250,000.00 | N/A |
| Revenue This Year | $6.84 | $17.96 |
| Revenue Next Year | $3.43 | $540.65 |
| P/E Ratio | $125.66 | ★ N/A |
| Revenue Growth | ★ 5.44 | N/A |
| 52 Week Low | $84.31 | $16.79 |
| 52 Week High | $111.53 | $42.21 |
| Indicator | FELE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 54.59 |
| Support Level | $97.53 | $34.05 |
| Resistance Level | $101.40 | $37.25 |
| Average True Range (ATR) | 1.94 | 2.43 |
| MACD | -0.30 | 0.03 |
| Stochastic Oscillator | 46.61 | 47.81 |
Franklin Electric Co Inc designs, manufactures, and distributes water and fuel pumping systems, composed of submersible motors, pumps, electronic controls, water treatment systems, and related parts and equipment. It has three segments; The Water Systems segment designs, manufactures and sells motors, pumps, drives, electronic controls, monitoring devices, and related parts and equipment for use in groundwater, water transfer, and wastewater, The Energy Systems segment designs, manufactures and sells pumps, pipe, sumps, fittings, vapor recovery components, electronic controls, monitoring devices, and related parts and equipment for use in fueling system applications and the Distribution segment sells and provides presale support and specifications to the installing contractors.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.